HOUSTON, Dec. 30, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, today
announced the appointment of Sean J.
Shapiro as Vice President of Sales, effective January 1, 2021.
Brad Hauser, Soliton's President
and CEO, commented, "We are very excited to have Sean join our team
during this pivotal time for the company as we anticipate clearance
of our 510(k) application for cellulite reduction during the first
quarter of 2021. Sean is a seasoned sales executive who has
successfully launched several aesthetic devices in the industry,
and we look forward to leveraging his extensive experience as we
prepare for the commercial launch of our RAP technology during the
first half of next year."
Most recently, Mr. Shapiro was Vice President of Commercial
Operations at Viveve Inc., a Women's Health Company which
manufactures patented CMRF Technology, where he recruited a sales
team which generated approximately $11
million in revenue in the year of launch. Prior to this, Mr.
Shapiro served as Senior Director of the North America Device
Division at Merz, where he successfully led a team of over 60 sales
professionals and helped launch Cellfina, a cellulite treatment
device which generated $15 million in
sales during the first year, along with Ultherapy, an industry
leading skin tightening device.
"I am truly looking forward to being a part of an established
veteran leadership team with such innovative technology that will
provide practitioners and patients superior results in cellulite
and tattoo removal," said Mr. Shapiro, Soliton vice president of
sales, "I am also excited to become a key contributor to the
commercial success and build a talented and determined sales
organization."
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product will use
rapid pulses of acoustic shockwaves as an accessory to lasers for
the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has filed a 510(k) application with
the FDA for clearance of its RAP device to improve the appearance
of cellulite and is investigating potential additional capabilities
of the RAP technology. The device is currently cleared in
the United States only for use in
tattoo removal and is not yet cleared for use to address
cellulite.
For more information about the Company, please visit:
http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to launch our RAP
device in the first half of 2021, our ability to receive FDA
clearance for the cellulite indication in the first quarter of
2021, our ability to effectively commercialize our products, and
the ability of the RAP device to successfully treat
cellulite. These statements relate to future events, future
expectations, plans and prospects. Although Soliton believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2019
we filed with the SEC on March 2,
2020 and updated from time to time in our Form 10-Q filings
and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales-301199206.html
SOURCE Soliton, Inc.